Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	51067
Country	France

Category	Oncology
Manuscript Type	Observational Study
Article Title	FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
Manuscript Source	Unsolicited Manuscript
All Author List	Angélique Vienot, Hortense Chevalier, Clément Bolognini, Elisabeta Gherga, Elodie Klajer, Aurélia Meurisse, Marine Jary, Stefano Kim, Christelle d'Engremont, Thierry Nguyen, Fabien Calcagno, Hamadi Almotlak, Francine Fein, Meher Nasri, Syrine Abdeljaoued, Anthony Turpin, Christophe Borg and Dewi Vernerey
Funding Agency and Grant Number
Corresponding Author	Angélique Vienot, MD, Doctor, Department of Medical Oncology, Besançon University Hospital, 3 Boulevard Alexandre Fleming, Besançon F-25030, France. angelique.vienot@gmail.com
Key Words	Advanced pancreatic cancer; First-line chemotherapy; FOLFOXIRI; FOLFIRINOX; Propensity score; Cohort study
Core Tip	This is the first study to compare FOLFOXIRI and FOLFIRINOX regimens head-to-head, to assess whether FOLFOXIRI contributes to better a balance of the toxicity/efficacy ratio in advanced pancreatic ductal adenocarcinoma. These findings do not suggest any therapeutic benefit of FOLFOXIRI compared to FOLFIRINOX in first-line chemotherapy. These results show that additional evaluation is not warranted in future clinical trials. FOLFIRINOX chemotherapy remains the standard of care first-line therapy in metastatic pancreatic ductal adenocarcinoma. Interestingly, the low hematological toxicity rates in both regimens underscore the interest of prophylactic administration of hematopoietic growth factors in routine use after each polychemotherapy cycle.
Citation	Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d’Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World J Gastrointest Oncol 2020; 12(3): 332-346

Received	2019-08-24 16:26
Peer-Review Started	2019-08-24 16:26
To Make the First Decision	2019-10-21 02:20
Return for Revision	2019-10-21 08:13
Revised	2019-12-26 15:42
Second Decision	2020-01-11 09:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-01-14 22:52
Articles in Press	2020-01-14 22:52
Publication Fee Transferred
Edit the Manuscript by Language Editor	2020-02-03 05:53
Typeset the Manuscript	2020-03-04 03:01

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com